Aortic & peripheral vascular disease
Treatment extent of femoropopliteal disease and clinical outcomes following endovascular therapy
Authors' conclusion
In this large real-world registry, SFA/PA EVT was associated with an increased risk for TLR at 2 years compared to the SFA or PA EVT groups, with favourable outcomes when using a DCB or drug-eluting stent in the SFA/PA EVT group.
Study context
- Population
- Patients with femoropopliteal disease undergoing endovascular therapy (EVT), K-VIS ELLA registry
- Exposure
- EVT of superficial femoral artery (SFA)/popliteal artery (PA) vs SFA vs PA
- SFAn = 2,404 limbsreference
- PAn = 155 limbs
- SFA/PAn = 383 limbs
- Outcome
- Target lesion revascularisation (TLR)
- Follow-up
- 2 years
Methodological detailsmulticentre registry (K-VIS ELLA)
- Multicentre registry (K-VIS ELLA)
Main finding
As reported in the abstract
TLR
Adjusted hazard ratio (CI)P value
SFA/PAvs SFA
1.48(1.09–2.00)
P = 0.008SFA/PAvs PAtrend
1.80(1.00–3.27)
P = 0.052Observational data: associations, not effects.
Further findings
Procedural success
Target lesion revascularisation (TLR) by device (drug-coated balloon (DCB))
- After overlap weighting, DCB use beneficial, with lowest TLR rate after SFA and SFA/PA EVT
Original publication
Treatment extent of femoropopliteal disease and clinical outcomes following endovascular therapy. EuroIntervention. Published 16 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →